Jean Zhao, Ph.D.
Affiliations: | Biological Chemistry and Molecular Pharmacology | Harvard Medical School, Boston, MA, United States |
Area:
PI3K, malignant transformationWebsite:
http://researchers.dana-farber.org/directory/profile.asp?pict_id=6939355Google:
"Jean Zhao"Cross-listing: Chemistry Tree
Children
Sign in to add trainee| Lukas Baitsch | post-doc | Harvard Medical School | |
| Shom Goel | post-doc | Harvard Medical School |
Collaborators
Sign in to add collaborator| National Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Guarducci C, Nardone A, Russo D, et al. (2024) Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Bergholz JS, Wang Q, Wang Q, et al. (2023) PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature |
| Ding L, Wang Q, Martincuks A, et al. (2023) STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. Journal For Immunotherapy of Cancer. 11 |
| Wang Q, Bergholz JS, Ding L, et al. (2022) STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications. 13: 3022 |
| Goel S, Bergholz JS, Zhao JJ. (2022) Targeting CDK4 and CDK6 in cancer. Nature Reviews. Cancer |
| Ni J, Kabraji S, Xie S, et al. (2022) p16-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications. 13: 1473 |
| Gaglia G, Kabraji S, Rammos D, et al. (2022) Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology. 24: 316-326 |
| Watt AC, Cejas P, DeCristo MJ, et al. (2021) CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48 |
| Spangle JM, Von T, Pavlick DC, et al. (2020) PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. Proceedings of the National Academy of Sciences of the United States of America |
| Fassl A, Brain C, Abu-Remaileh M, et al. (2020) Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances. 6: eabb2210 |